CSBR vs. GNTA, ENTX, CDTX, IKNA, LENZ, ALGS, TSBX, ELUT, ATRA, and AVRO
Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Genenta Science (GNTA), Entera Bio (ENTX), Cidara Therapeutics (CDTX), Ikena Oncology (IKNA), LENZ Therapeutics (LENZ), Aligos Therapeutics (ALGS), Turnstone Biologics (TSBX), Elutia (ELUT), Atara Biotherapeutics (ATRA), and AVROBIO (AVRO). These companies are all part of the "biological products, except diagnostic" industry.
Champions Oncology (NASDAQ:CSBR) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 45.7% of Champions Oncology shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Champions Oncology presently has a consensus price target of $7.50, indicating a potential upside of 51.21%. Given Champions Oncology's higher possible upside, equities analysts clearly believe Champions Oncology is more favorable than Genenta Science.
Champions Oncology has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Genenta Science has a net margin of 0.00% compared to Champions Oncology's net margin of -19.76%. Genenta Science's return on equity of 0.00% beat Champions Oncology's return on equity.
Champions Oncology received 144 more outperform votes than Genenta Science when rated by MarketBeat users. However, 83.33% of users gave Genenta Science an outperform vote while only 60.08% of users gave Champions Oncology an outperform vote.
Champions Oncology has higher revenue and earnings than Genenta Science.
In the previous week, Champions Oncology had 19 more articles in the media than Genenta Science. MarketBeat recorded 23 mentions for Champions Oncology and 4 mentions for Genenta Science. Champions Oncology's average media sentiment score of 1.04 beat Genenta Science's score of 0.59 indicating that Champions Oncology is being referred to more favorably in the media.
Summary
Champions Oncology beats Genenta Science on 8 of the 14 factors compared between the two stocks.
Get Champions Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Champions Oncology Competitors List
Related Companies and Tools
